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B-Cell Precursors: 
Immunophenotypic Features in 
the Detection of Minimal Residual 
Disease in Acute Leukemia
Olga Chernysheva, Lyudmila Yuryevna Grivtsova, 
Alexander Popa and Nikolay Nikolayevich Tupitsyn
Abstract
Minimal residual disease (MRD) as a tool to monitor response to therapy is both 
a criterion for detailed risk stratification and an independent prognostic factor in 
childhood acute lymphoblastic leukemia (ALL). Immunological assays particularly 
flow cytometry (FC) are priority methods in MRD monitoring. Multicolor flow 
cytometry makes it possible to most fully characterize the immunophenotype of 
tumor B lymphoblasts and reveal leukemia-associated immunophenotypes not only 
according to the CD58 and CD38 antigens but also as an additional criterion of aber-
rancy. This allows you to identify and select individual criteria for further monitor-
ing of minimal residual disease for each patient with ALL. The aim of this chapter 
is to compare immunophenotyping features of normal B-cell precursors and 
B-lymphoblasts in acute leukemia and to show possibilities of use of a leukemia-
associated immunophenotype in monitoring of the MRD.
Keywords: bone marrow, B-cell precursors, acute leukemia,  
leukemia-associated immunophenotype, flow cytometry, minimal residual disease
1. Introduction
Control of response to chemotherapy is an intrinsic part of current treatment 
protocols [1–5]. Assessment of response in key points of chemotherapy programs 
helps both to stratify patients by risk groups more accurately and to avoid serious 
chronic side effects and patient overtreatment [6–12]. In case of acute leukemia, 
the number of tumor blasts undetectable in bone marrow (BM) morphologically at 
different therapy stages or minimal residual disease (MRD) is a criterion for such 
assessment.
In adult patients, problems of most significant points of immunological detec-
tion and the role of MRD levels are a matter of discussion [2]. The MRD signifi-
cance is demonstrated in full in pediatric oncology. The MRD is of importance both 
in prognosis of acute lymphoblastic leukemia (ALL) and in prediction of recurrence 
[13]. Key points for MRD assessment are determined as well as their clinical signifi-
cance and MRD levels that help in detailed risk stratification of patients [1].
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Immunological quantification of MRD cells solves different problems depending 
on chemotherapy stages. In the middle of induction therapy (day 15), it evaluates 
primary response [14]. While at the end of induction therapy (day 33), the purpose 
is final risk stratification of patients with respect to clinical and immunological 
prognostic factors [1, 14, 15]. MRD assessment at the end of induction consolida-
tion (day 78) identifies a patient group with so called slow response. These patients 
remain MRD-positive by days 15 and 33 and reach MRD-negativity by day 78 only. 
This group is characterized by good prognosis [3].
Many international research groups have developed flow cytometry (FC) proto-
cols for MRD diagnosis; however, there is not a common approach yet. The St Jude 
Children’s Research Hospital (Memphis, USA) has proposed a simplified 3-color FC 
assay to detect MRD cells on day 15 of induction therapy [16] that is based on elimi-
nation of normal B-cell precursors (BCP) under the effect of corticosteroids [17] 
that are a basis for therapy at the given stage. The BFM international study group 
has developed an MRD monitoring protocol basing on the detection of B-LP with 
aberrant (leukemia-associated) immunophenotype (LAIP). Antigens CD58 and 
CD38 are most common markers to characterize the aberrant immunophenotype 
[18, 19]. However, tumor lymphoblasts show no aberrance by these antigens [20]. 
There are no clearly identified alternative combinations of aberrant markers.
In ALL from T-cell precursors (T-ALL), there are no clearly cut criteria for MRD 
assessment [21] and research in this field is ongoing.
The aim of this chapter is to compare immunophenotyping features of normal 
B-cell precursors and B-lymphoblasts in acute leukemia and to show possibilities of 
use of a leukemia-associated immunophenotype in monitoring of the MRD.
2. Materials and methods
The study involved 191 ALL cases (160 B-ALL [142—primary diagnosis, 18—
diagnosis in relapse] and 31 T-ALL). The diagnosis was made basing on a combina-
tion of morphocytochemical and immunophenotyping assays of BM puncture 
biopsies.
In most cases (88.8% of B-ALL and 87.1% of T-ALL), the immunophenotyping 
at diagnosis was performed by 3-color FC (at least 20 markers was analyzed). The 
immunophenotyping using EuroFlow 8-color standardized panels was made in 
11.2% of B-ALL and 12.9% of T-ALL cases. Lineage of blasts was determined using 
ALOT (acute leukemia orientation tube) (Table 1).
A more accurate B-ALL (Table 2) or T-ALL (Table 3) 8-color standardized 
panel was used depending upon the identified blast lineage. The BCP aberrance was 
assessed basing on expression of the following antigens: CD58, CD38, CD81, CD9, 
CD123, CD66c, CD13, CD33, CD20, CD21, and CD24; T-cell precursors (TCP) were 
characterized with respect to CD99, CD56 expression.
MRD quantification was made in 397 BM specimens from ALL patients at differ-
ent therapy stages (days 15, 33, and 78, Table 4).
No./
fluorochrome
Markers
FITC PE PerCP-cy5.5 PE-cy7 APC APC-117 V450 V500
1 cy
MPO
cy
CD79a
CD34 CD19 CD7 sm
CD3
cy
CD3
CD45
Table 1. 
Acute leukemia orientation tube.
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At diagnosis, every BM specimen was characterized both morphologically and 
immunologically. Myelogram count was made by two morphologists (250 cells 
each) on Giemsa stained BM smears. The following M-types were identified basing 
on standard morphological criteria for the number of blasts: M1—specimens with 
≤5% of blasts, M2—specimens with 5.0–25.0% of blasts, and M3—specimens with 
≥25% of blasts. After that, a more detailed analysis was made, and the morphologi-
cal criteria were compared with immunological findings. Detailed analysis of MRD 
levels was made in M1, M2, and M3 specimens. Subgroups of specimens within 
each group were identified with respect to the number of MRD cells. The subgroups 
were identified according to the BFM protocol for MRD assessment on induction 
chemotherapy as follows: standard risk <0.1% (including negative cases), medium 
risk 0.1–10.0%, and high risk ≥10%/the level of 0.01% of tumor cells in a specimen 
was taken as a standard threshold for MRD negativity.
No./
fluorochrome
Markers
FITC PE PerCP-cy5.5 PE-cy7 APC APC-117 V450 V500
1 CD58 CD66c CD34 CD19 CD10 CD38 CD20 CD45
2 cyIgM CD33 CD34 CD19 CD117 + sIgM sIg-λ sIg-κ CD45
3 nuTdT CD13 CD34 CD19 CD22 CD24 CD9 CD45
4 CD15 + CD65 NG2 CD34 CD19 CD123 CD81 CD21 CD45
Table 2. 
EuroFlow consortium 8-color standardized panel for B-ALL diagnosis.
No./fluorochrome Markers
FITC PE PerCP-cy5.5 PE-cy7 APC APC-117 V450 V500
1 nuTdT CD99 CD5 CD10 CD1a smCD3 cyCD3 CD45
2 CD2 CD117 CD4 CD8 CD7 smCD3 cyCD3 CD45
3 TCRγδ TCRαβ CD33 CD56 cyTCRαβ smCD3 cyCD3 CD45
4 CD44 CD13 HLA-DR CD45RA CD123 smCD3 cyCD3 CD45
Table 3. 
EuroFlow consortium 8-color standardized panel for T-ALL diagnosis.
ALL immuno-subtype
FC color number
MRD monitoring points
Day 15 Day 33 Day 78
3 col. 4–6 col. 8 col. 3 col. 4–6 col. 8 col. 3 col. 4–6 col. 8 col.
В-ALL Total 139 148 54
No. 59 68 12 51 79 18 3 38 13
Percentage 42.4 49.0 8.6 34.4 53.4 12.2 5.6 70.4 24.0
Т-ALL Total 30 26 —
No. 9 19 2 6 18 2 — — —
Percentage 30.0 63.3 6.7 23.1 69.2 7.7 — — —
Table 4. 
The number of analyses at each MRD monitoring point.
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Statistical analysis was made using IBM-SPSS Statistics v.17 software. Parametric 
data were analyzed by comparison of means using Student’s t-test. Comparison of 
nonparametric data was made by Pearson’s χ2-test.
3. Results
3.1 General patient characteristics
A total of 186 patients with ALL (five patients were treated in debut and in 
relapse of the disease) managed at the N.N. Blokhin Cancer Research Center during 
2006 through 2017 were entered in the study.
The B-ALL group included 155 patients 1–18 years of age: 78 boys (48.7%) and 
82 girls (51.3%) (Table 5). In 142 cases (88.8%), the diagnosis was made at the 
disease onset. In 18 cases (11.2%), the diagnosis was made in recurrence stage. Five 
patients were followed up both in the debut and recurrences stages.
The T-ALL group consisted of 31 patients aged 2–17 years including 26 boys 
(83.9%) and 5 girls (16.1%) (Table 6).
Treatment was given according to the ALL IC BFM 2002 and 2009 protocols. 
Data on risk stratification are shown for 79 patients with B-ALL receiving treatment 
by the ALL IC BFM 2009 protocol (data for 63 patients with B-ALL onset are not 
available). The majority of patients (67.1%) were classified into an intermediate risk 
group. Only 5.1% of patients were a high risk group. And 27.8% of patients were 
assigned to a standard risk group.
71.0% of T-ALL patients received treatment by ALL IC BFM 2009 protocol. The 
majority of patients (72.7%) were classified into an intermediate risk group. Other 
patients (27.3%) were assigned to a high risk group.
Characteristic Number Percentage
Gender М 29 83.9
F 7 16.1
Age 1–17 years (mean 7.3 ± 4.7 years)
Time of diagnosis Debut 31 100
Pre-T-cell 12 38.7
Cortico-thymocytic 19 61.3
Table 6. 
Patient characteristics in the T-ALL group.
Characteristic Number Percentage
Gender M 78 48.4
F 83 51.6
Age 1–18 years (mean 5.9 ± 0.3 years)
Time of diagnosis Debut 142 88.8
Recurrence 18 11.2
Immunosubtype Pre-pre-В 150 93.8
Pro-В 10 6.2
Table 5. 
Patient characteristics in the B-ALL group.
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MRD monitoring was made on days 15, 33, and 78 of chemotherapy according 
to the treatment protocols used at the Research Institute of Pediatric Oncology and 
Hematology of the FBI N.N. Blokhin NMRCO and international recommendations.
3.2 ALL from B-cell precursors
3.2.1 Immunological characterization of blasts at primary diagnosis
Table 7 shows B-lymphoblast immunophenotype characteristics at primary 
diagnosis. These immunological characteristics were used further in MRD 
monitoring.
CD58 and CD38 are currently most commonly used antigens as main criteria of 
tumor B-lymphoblast aberrance. Blasts are considered aberrant if they are char-
acterized by overexpression of CD58 in combination with low or no expression of 
CD38 (immunophenotype CD58++CD38low/−, Figure 1).
Analysis for this antigen combination demonstrated that blasts do not always 
have the CD58++CD38low/− immunophenotype, that is, aberrance by both antigens is 
found in 54.3% of cases only (Table 8). Figure 2 shows an example of no aberrance 
by CD58 and CD38 antigens.
The following markers were studied as additional criteria of aberrance: CD123 
(Figure 3), CD66c, CD81 (Figure 4), CD9, CD21, CD24 with their expression 
presented in Table 9. Figures 3 and 4 show an example of aberrant expression of 
CD123 and CD81 in B-lymphoblasts at primary diagnosis.
3.2.2 Immunophenotypic characterization of blasts at relapse
A total of 18 patients were examined at relapse of the disease. Five patients were 
examined at both disease onset and relapse. Blast characterization was made using a 
Antigen No. of cases 
analyzed
Frequency of Ag-positive cases (%)
CD10 142 93.0
CD34 139 74.1
nuTdT 24 100.0
smCD22 137 50.3
CD20 129 14.7
Pan-myeloid (CD13, CD33) 137 46.0
CD58++CD38low/− 50 54.0
CD38+/++ 93 54.8
Additional criteria of aberrance
CD123 8 100.0
CD66c 8 75.0
CD81 7 14.3
CD9 8 87.5
CD21 7 0.0
CD24 7 100.0
Table 7. 
Tumor blast immunophenotype characteristics at primary diagnosis at disease onset.
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Figure 1. 
Blasts with aberrant immunophenotype CD58++/CD38low. Cytogram A: blasts (gate 2, green) demonstrate 
bright CD19 expression (X-axis) against side scattering parameters (SSC, Y-axis). Cytogram B: B-lymphoblasts 
demonstrate bright CD58 expression (Y-axis) in combination with low CD38 expression (X-axis) as compared 
to normal BCP (CD58+CD38+, gate 4).
CD58/CD38 expression Number Percentage
CD58++/CD38low/− 25 54.3
CD58+/CD38low/− 2 4.3
CD58++/CD38+ 8 17.4
CD58+/CD38+ 11 24.0
Total 46 100.0
Table 8. 
Blast immunophenotypes with respect to CD58 and CD38 expression at primary diagnosis.
Figure 2. 
Tumor B-lymphoblasts with immunophenotype CD58+/CD38+. Cytogram A: tumor B-lymphoblasts are 
identified basing on CD19 expression (X-axis) and low SSC characteristics (Y-axis). Blasts (CD45lowCD19+) 
are characterized by bright CD38 expression (X-axis) in combination with normal CD58 expression (Y-axis) 
(cytogram B).
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3-color FC protocol in 66.7% (12/18) patients. In six patients (33.3%), immunophe-
notyping used the EuroFlow consortium 8-color protocol.
Expression of main CD58/CD38 aberrance markers at disease recurrence was 
assessed in 13 patients.
Blast immunophenotype with respect to CD58 and CD38 expression intensity 
as compared with the primary diagnosis changed in 2 of 5 cases. In the first case, 
blasts at primary diagnosis were immunophenotypically close to normal BCP as 
concerns CD58 and CD38 expression (CD58+CD38++), while acquiring aberrant 
CD58 and CD38 expression (CD58++CD38+) at relapse. In the second case, on the 
opposite, blasts lost aberrant CD38 sign and became close to normal non-tumor 
B-lymphoblasts by this antigen expression.
Figure 3. 
Tumor B-lymphoblast aberrance by CD123 at primary diagnosis. Cytogram A: blasts (gate 1, red) are detected 
by low CD45 expression (X-axis) and low SSC characteristics (Y-axis). Cytogram B: tumor lymphoblasts 
demonstrate bright expression of pan-B-cell antigen CD19 (Y-axis) in combination with bright (aberrant) 
CD123 expression (X-axis).
Figure 4. 
Normal (A) and aberrant (B) expression of CD81 on B-LP. Cytogram A: normal bright CD81 expression 
on tumor B-lymphoblasts (green) in X-axis (CD81) against Y-axis (CD45) coordinates. Cytogram B: tumor 
B-lymphoblasts (green) with aberrant (weak) CD81 expression in X-axis (CD81) against Y-axis (CD45).
Normal and Malignant B-Cell
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3.2.3 MRD assessment on day 15 of therapy
We compared morphological and immunological findings from BM analysis on 
day 15 of therapy. In group M1, morphological and FC data were fully similar (no 
blasts by morphology and complete MRD negativity [MRD cells < 0.01%] by FC) in 
11.5% of cases.
Specimens from the M1 group were characterized by a marked percentage of 
lymphocytes (mean > 60.0%). The presence of MRD-positive specimens (FC) in 
the M1 group (good morphological response) may be explained by blast mimicry, 
that is, similarity with lymphocytes. This makes difficult accurate morphological 
verification of residual leukemic blasts.
In group M1, there was no contradiction between morphological and FC data. Most 
M3 specimens (85.7%) contained ≥10.0% of MRD-positive cells by FC. The fraction of 
MRD-positive cells was 5.5% in one case only; that is, in terms of FC, this patient might 
be referred to the intermediate risk group and did not require therapy intensification.
Comparison of two FC protocols for MRD monitoring on day 15 (3-color St. Jude 
[28] based on identification of CD10+/CD34+ BCP among BM mononuclear frac-
tion, and BFM protocol based on identification of BCP with aberrant immunophe-
notype among nucleated cells [NC]) demonstrated that the mononuclear approach 
was a more strict criterion for risk stratification of patients.
MRD on day 15 of induction therapy in B-ALL is always represented by BCP. Their 
identification is based on detection of CD10 and CD34 expression or no expression 
of pan-leukocyte antigen CD45 and combination of the above mentioned markers in 
B-cells. Quantification of MRD cells on the basis of each of the progenitor markers 
demonstrated that CD10 was the most reliable criterion for evaluation of BCP cells on 
day 15 of chemotherapy in children with pre-pre-B ALL. While in pro-B B-ALL, the 
count of BCLP should be made basing on nuTdT-positive cyCD22-expressing B-cells.
CD58/CD38 expression was assessed on day 15 of induction chemotherapy in 
28 patients. All BCP, that is, MRD cells demonstrated aberrant immunophenotype 
CD58++/CD38low only in 15 of 28 patients (54%) (Figure 5).
CD58++/CD38low/− BCP content was analyzed in patients with no aberrance by 
this antigen combination at primary diagnosis (n = 11). The proportion of CD10+ 
B-cells was similar to that of CD58++/CD38low/− BCP in four specimens only. This 
example is illustrated in Figure 5. In the remaining cases, the number of CD58++/
CD38low BCP was less than the number of CD10+ B-cells.
The analysis demonstrated a significant predominance of MRD on day 15 of 
therapy in pro-B ALL as compared to pre-B (p = 0.016).
Day 15 of induction chemotherapy is characterized by BM hypocellularity and a 
marked fraction of debris that can interfere with results (Figure 6). To avoid this, 
Antigen No. of cases studied Frequency of Ag-positive cases (%)
nuTdT 31 80.6
CD34 31 19.4
CD10 31 38.7
CD4+CD8+ 31 35.5
CD1a 31 54.8
CD5 31 90.3
CD7 31 96.8
Table 9. 
Detection frequency of antigens associated with various TCP differentiation stages in T-ALL.
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a nucleotropic Syto die (Sito16 and Sito16 in our study) was included in the MRD 
detection panel.
In the group, as a whole MRD-negative status was found on day 15 of induction 
chemotherapy in 11.5% of patients, which allowed reduction in anthracycline dose 
to be considered with respect to clinical prognostic factors without the risk of recur-
rence in this subgroup.
3.2.4 MRD assessment on day 33 of therapy
MRD quantification was based on count of CD58++CD38low/− BCP. If specimens 
demonstrated no aberrance by this antigen combination at primary diagnosis, MRD 
was assessed by CD58++CD10++ or CD38lowCD10++ combinations.
According to the morphological risk stratification criteria, all specimens 
contained less than 5.0% of blasts (1.2% ± 0.1, n = 80) and were included in the 
M1 group. There were no blasts in 6.25% of specimens (5/80). MRD-positivity by 
immunology was identified in 40.0% of cases (32/80). In two patients (2.5%), MRD 
cells were >1.0%. There were no high risk specimens (MRD ≥ 10.0%) in our study.
CD58 and CD38 primary tumor aberrance on day 33 of induction chemotherapy 
was assessed in 50.0% of patients. CD58 aberrance was found in 28 of 40 cases 
(70%), and CD38 aberrance was detected in 60.0% of cases (24/40). 55.0% of cases 
(22/40) were CD58/CD38 aberrant and 45.0% (18/40) demonstrated no aberrance.
Figure 5. 
BCP immunophenotype features on day 15 of induction therapy. Cytogram A: 16.6% CD19+CD45low BCP (gate 
3, green) in CD19 (X-axis) against CD45 (Y-axis) coordinates. The cells demonstrate bright CD10 (cytogram 
B), CD19 (X-axis) expression against CD10 (Y-axis) and marked CD34 expression (cytogram C), CD19 
(X-axis) against CD34 (Y-axis). MRD cells show aberrant immunophenotype CD58++CD38low (cytogram D, 
CD38 [X-axis] against CD58 [Y-axis]).
Figure 6. 
Day 15 of induction therapy. The specimen has much debris. Cytogram A: NC detection basing on expression 
of nucleotropic die Syto16 against SSC. The specimen has 3.65% of NC (gate 1, red). Cytogram B: evaluation 
of B-cell fraction (gate 2, blue): CD19 (X-axis) against SSC. The B-cell fraction without NC is 0.57%, with 
recount for NC CD19+ cells are 15.6% in this specimen. CD34+ BCP are 0.0021% without NC, that is, MRD-
negativity. Recount with respect to Syto16 results in CD34+ BCP being 0.06%, that is, MRD-positivity.
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Cases without CD58/CD38 aberrance at the primary diagnosis were examined 
for markers identifying cells of residual tumor by the literature.
We analyzed CD81, CD123, CD9, CD21, CD24 expression in 21 BM specimens. 
As a result, most informative marker combinations for detection of aberrant 
B-lymphoblasts were identified: combinations of CD58 or CD38 with CD10 
(aberrant immunophenotypes CD58++CD10+ or CD38+CD10++) were the most 
informative in terms of FC. In case of CD20-positive ALL MRD could be detected 
by asynchronous CD20 and CD34 expression (aberrance characterized by 
CD34+CD20+ phenotype, Figure 7). In most cases, residual tumor may be detected 
by marked expression of CD123 in combination with weak or no expression of 
CD81 (aberrant immunophenotype CD123++CD81low, Figure 8). In some cases, CD9 
monomorphic tumor expression especially in combination with one of clear-cut 
Figure 7. 
MRD quantification basing on asynchronous expression of stage-specific Ag CD34/CD20 in a patient with 
CD20+ pre-pre-B B-ALL immunosubtype. Cytogram A: tumor B-lymphoblasts (CD45lowCD19+) at primary 
diagnosis (X-axis CD20 against Y-axis CD10), of which 60.0% express CD20. Cytogram B: MRD detection 
basing on simultaneous CD20 (X-axis) and CD34 (Y-axis) expression. MRD cells are 0.027% of NC specimen, 
that is, MRD-positivity.
Figure 8. 
MRD quantification basing on aberrance by CD58/CD38 and CD123/CD81. Cytogram A: BCP detection 
basing on bright CD10 (Y-axis) expression in combination with low CD45 expression (X-axis), gate 4 
(0.03% of NC) within CD19+ B-cells. Cytogram B: BCP are characterized CD58 overexpression (Y-axis) 
in combination with no CD38 expression (X-axis) and demonstrate CD123++CD81low immunophenotype 
(cytogram C: CD123 [Y-axis] against CD81 [X-axis]). Therefore, B-lymphoblasts are aberrant by all four Ag 
analyzed, and there are no normal BCP in this specimen. Aberrant BCP are 0.027% of NC specimen, that is, 
MRD-positivity.
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aberrance criteria (CD58++, CD123++, CD38low, CD81low, Figure 9) are a sign of 
tumor aberrance and criterion for MRD assessment.
In cases with monomorphic co-expression of myeloid antigens (CD66c, CD13 or 
CD33), MRD assessment may be based on these markers.
Of the whole patients, cohort (80 patients) MRD-negative status was deter-
mined by FC in 60.0% (48 patients), and 40.0% (32 patients) were found MRD-
positive. Comparison of basic morphological and immunological characteristics in 
these groups identified significant differences in the number of blasts (p = 0.012) 
and CD19+ B-cells (p = 0.044).
Basing on FC quantification of MRD, most patients (65.0%) receiving treatment 
by ALL IC BFM 2009 protocol were included in the intermediate risk group.
3.2.5 MRD assessment on day 78 of therapy
MRD assessment on day 78 of therapy was made in 42 patients and was based on 
detection of BCP with aberrant immunophenotype (CD58++CD38low/−).
As recommended by BFM protocols, BM specimens were divided into MRD-
positive and MRD-negative subgroups. Most BM specimens were MRD-negative 
(n = 27), and 15 of 42 specimens (35.7%) were MRD-positive.
In 14 patients, MRD status was assessed at three points of treatment protocol 
(days 15, 33 and 78). Seven of them achieved MRD-negativity by day 78 and met the 
criterion of slow response to therapy.
3.2.6 MRD assessment after 1 block of anti-relapse therapy (day 35)
After 1 block of anti-recurrence therapy, MRD was detectable in 15 BM speci-
mens. By FC, 40.0% of patients (0.004 ± 0.0008%, n = 6) were MRD-negative and 
60.0% of patients (7.3 ± 4.8%, n = 9) were MRD-positive with 77.0% of the MRD-
positive specimens (0.9 ± 0.6%, n = 7) containing <5.0% of blasts by morphological 
study.
3.2.7 MRD monitoring on targeted therapy
In our study, one patient with early recurrence of ALL (pre-pre-B immuno-
subtype) received anti-recurrence targeted agent blinatumomab (biospecific 
Figure 9. 
MRD quantification basing on aberrance by CD9 and CD81. Cytogram A: tumor B-lymphoblasts 
(CD45lowCD19+) at primary diagnosis with bright nuTdT expression (Y-axis) in combination with 
monomorphous CD9 overexpression (X-axis). Cytogram B: tumor cells are aberrant by CD81 (X-axis CD81 
against Y-axis CD45). As compared to residual normal BCP (gate 4, pink) with bright CD81 expression, 
tumor B-lymphoblasts demonstrate low (aberrant) Ag expression. Cytogram C: MRD detection basing on 
bright monomorphous CD9 overexpression (Y-axis) in combination with low CD81 expression (X-axis) (gate 
4, dark blue). They are 0.015% of NC specimen: MRD-positivity.
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anti-CD19 monoclonal antibody). Blinatumomab mechanism of action involves 
specific binding with CD19+ cells and recruitment of effector T-cells to enhance 
response. According to the literature data, CD19 is not expressed on cells dur-
ing blinatumomab therapy which makes difficult BCP identification. We chose 
an alternative BCP identification procedure to monitor MRD in this patient 
category: BCP identification and characterization on blinatumomab (anti-CD19) 
therapy should be based on expression of cyCD22 and nuTdT due to lost of CD19 
expression.
3.3 ALL from T-lineage precursors
A total of 31 patients with T-ALL were included in our study. About 61.3% of 
patients (n = 19) presented with cortico-thymocytic immunosubtype (CD1a expres-
sion and/or the presence of CD4+CD8+ population) as determined by primary 
immunophenotyping. Table 9 shows characteristics of blast immunophenotype at 
the stage of primary diagnosis.
Since T-cell ontogenesis is characterized by the absence of T-cell progenitors in 
normal BM, MRD monitoring by FC at all therapy stages involves detection and 
count of TCP.
According to BFM protocol, MRD detection in T-ALL is based on identifica-
tion of T-cells with aberrant immunophenotype within CD7-positive fraction. 
However, CD7 demonstrates a broad range of expression and is present not only on 
TCP (NK-cells and myeloid progenitor cells); therefore, a cytometric protocol for 
TCP detection in BM (MRD cells) was developed that was based on expression of 
pan-T-cell antigen CD3 in cytoplasm (cyCD3) as the most stable lineage-specific 
pan-T-cell antigen. Choice of appropriate antigen clone is an important requirement 
for detection of cytoplasmic CD3 expression. For instance, SK7 clone is used to 
detect membrane determinant, while UCHT-1 binds to cytoplasmatic determinant. 
So, only UCHT-1 monoclonal antibody should be used in analysis of cyCD3.
In our study, quantification of TCP in BM was based on detection of subpopula-
tions smCD3−CD7+, smCD3−TdT+, smCD3−CD1a+, and CD4+CD8+ within cyCD3-
positive BM T-cells at all time points of MRD monitoring.
To simplify recount and exclusion of debris, the quantification was made within 
NC of specimens as identified by Syto dies. The highest values were used as recom-
mended by MRD detection protocols.
3.3.1 MRD assessment on day 15 of therapy
Quantification of residual blasts on day 15 of induction chemotherapy was made 
in 30 BM specimens.
The morphological and immunological findings were as a whole similar. 
The group M2 was heterogeneous demonstrating variability in blast numbers 
and MRD levels; however, these specimens belonged to intermediate risk group 
both by M-subtypes and MRD levels and therefore did not interfere in patient 
stratification.
BM characteristics on day 15 of treatment were analyzed with respect to T-ALL 
immunosubtype. The pre-T immunosubtype was characterized by significantly 
higher MRD level on day 15 as compared to cortico-thymocytic one (p = 0.044).
About 76.2% of patients composed the intermediate risk group (according to 
ALL-IC-BFM 2009 protocol), and 23.8% were stratified into the high risk group. 
There were no patients meeting criteria for standard risk in our study
Basing on MRD level on day 15 of induction chemotherapy, 25.0% were trans-
ferred from the intermediate to the high risk group.
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It is important to note that MRD negativity was not reported on day 15 of induc-
tion chemotherapy in any of the patients, that is, none of the patients achieved 
complete leukemic cytoreduction in the middle of remission induction therapy.
3.3.2 MRD assessment on day 33 of therapy
Quantification of residual blasts on day 33 of induction chemotherapy was made 
in 26 patients.
Most BM specimens (25/26) were included into group M1, while there was only 
one specimen meeting the M2 criteria. None of the specimens was included in 
group M3 basing on morphological characteristics.
We compared morphological and immunological findings. Specimens from the 
standard and intermediate risk groups were analyzed in detail with respect to MRD 
content.
All BM specimens from group M1 were MRD-positive. Basing on the immu-
nological criteria, 16.0% of BM specimens (n = 4) were included in the standard 
risk group (MRD < 0.1%). The intermediate risk group consisted of 20 of 25 BM 
specimens (80.0%). One BM specimen from this group contained no blast cells by 
morphology, though FC discovered 2.69% of MRD cells (Figure 10).
One specimen was included in the high risk group by MRD assessment 
(MRD ≥ 10.0%).
Note that specimens from this sample demonstrated rather high lymphocytosis 
(more than 28.0%).
By morphological criteria, only one BM specimen was included in the M2 group 
(blasts 10.8%), while by immunological characteristics, this specimen might be 
referred to the standard risk group (MRD cells 0.04%).
CD7 in combination with CD3 are used to assess MRD in T-ALL in the BFM 
protocol. However, CD7 is commonly found on myelokaryocytes including both 
lymphoid and myeloid progenitors. Basing on ontogenetic characteristics of expres-
sion of T-lineage antigens, we propose to detect TCP (that is MRD cells) by expres-
sion of cytoplasmatic CD3 as the earliest lineage-specific T-cell marker.
Comparison of these two approaches to MRD monitoring (the standard BFM 
protocol basing on MRD cell count within CD7-positive cells and MRD count 
within cyCD3+ cells), both on days 15 and 33 of induction chemotherapy allowed us 
to make the conclusion that MRD quantification in T-ALL by detection of cyCD3+ 
smCD3− populations is more accurate.
Figure 10. 
An example of MRD-positivity with no blasts in the BM specimen by morphology on day 33 of therapy. 
Cytogram A: shows NC of the specimen (gate 1, red) basing on reactivity with Syto16 (X-axis) against 
SSC. Cytogram B: cyCD3+ T-cells within NC (gate 2, blue) with low SSC parameters (cyCD3, X-axis 
against SSC Y-axis). Cytogram C: CD7, X-axis against smCD3, Y-axis (gate 2) shows TCP (MRD cells) with 
CD3+CD7+ smCD3− immunophenotype that are 2.69% of myelokaryocytes: MRD-positivity.
Normal and Malignant B-Cell
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4. Conclusions and discussion
Successful treatment of patients with acute leukemia is associated with escala-
tion of chemotherapy doses which requires effective monitoring of response. 
Assessment of response in key points of chemotherapy protocols helps both to 
stratify patients by risk groups more accurately and to avoid serious long-term side 
effects or patient overtreatment.
Search for adequate approaches to assessment of response was started since the 
1970s. For a long time, response to therapy was assessed basing on the number of 
blasts in BM specimens as determined by morphological study, and as a result so 
called M-types were defined as follows: M1: <5.0% of blasts, M2: 5–25% of blasts, 
and M3: ≥25% of blasts [22].
However, the progress in molecular methods such as polymerase chain reaction 
(PCR) and flow cytometry (FC) allowed quantification of minimal number of 
residual blasts at submicroscopic level (<0.01%).
In recent years, quantification of residual tumor cells in BM, that is, minimal 
residual disease (MRD) was a main criterion of response to chemotherapy. Opposite 
to myeloid leukemias when molecular genetic methods play the leading role in MRD 
detection, it is immunological approaches involving FC alone that can detect MRD 
cells in more than 95.0% of cases [23].
Both PCR and FC have their advantages and disadvantages. Implementation of 
multiparameter FC able to assess up to 12 parameters of a single cell and develop-
ment of computer software that allows tens of millions of cells to be examined 
makes FC close to PCR by sensitivity [24]. FC is currently the most rapid and less 
costly approach to MRD monitoring.
In adults, problems of the most important detection points are a matter of 
discussion [2]. The MRD significance is most vivid in pediatrics. MRD is found to 
play a role both in ALL prognosis and recurrence prediction [1]. Key points of MRD 
monitoring and their clinical significance have been determined as well as MRD 
levels that allow detailed risk stratification of patients.
It is in childhood oncology that the MRD effects of the patient faith have been 
studied [1, 25]. The current protocols defined three mandatory time points such as 
the middle and end of remission induction chemotherapy (days 15 and 33) and the 
end of consolidation induction (day 78).
MRD monitoring plays different roles at different chemotherapy stages. The 
most important point in terms of the patient faith is the middle of induction chemo-
therapy when primary tumor response and prognosis are determined.
For a long time, there were multiple attempts to make the earliest possible 
assessment of response. One of the approaches is count of blasts in peripheral blood 
on day 8 of treatment. Patients with blast reduction below 1000 cells/mcl are a 
group of good response and good prognosis. However, the blast clearance on day 8 
is found to reflect response to steroids only [5], while MRD level on day 15 of induc-
tion chemotherapy is the most accurate reflection of leukemic cytoreduction, that 
is, primary response to treatment [5, 14].
The key moment is the selection of good response patients (MRD < 0.01%) in 
whom reduction of anthracycline dose may be considered [11, 26]. In our study, FC 
discovered MRD-negativity in 11.5% of patients in whom reduction of anthracy-
cline dose could be considered. These patients did not develop recurrence.
The situation in BM by day 15 of therapy is unique in terms of immunology. 
Since BCP are highly sensitive to glucocorticoids [17] that are the basis for treatment 
at the given stage, these cells are fully eliminated from BM [16]. This observation 
was a basis for a FC protocol developed by the St Jude Children’s Research Hospital 
(Memphis, USA) study group for detection of MRD cells on day 15. This protocol 
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involves MRD monitoring within BM mononuclear fraction, while the BFM proto-
col uses recount for NC in the specimen.
We compared the two approaches to conclude that recount for NC (the St. Jude 
Hospital protocol) is the most robust criterion for risk stratification of patients. 
Moreover, analysis of MRD cell immunophenotype with respect to CD58 and CD38 
expression demonstrated that the number of CD10+ B-cells was similar to that of 
CD58++/CD38low/− BCP in 36.4% of cases only. While the number of CD58++CD38low 
BCP was less as compared to CD10+ B-cells in the remaining specimens of aberrant 
BCP. We conclude therefore that quantification of MRD should be based on detec-
tion of BCP rather than of aberrant blasts.
MRD cells on day 15 are BCP. We used a variety of monoclonal antibodies for 
their monitoring. In pre-pre-B and pre-B ALL immunosubtypes, it is just enough to 
count CD34+ and/or CD10+ BCP. In case of pro-B immunosubtype (CD10− and/or 
CD34−), MRD detection should involve a combination of nuclear TdT with cyto-
plasmatic CD22 or CD79α that show stable expression as demonstrated already in 
early studies of B-cell ontogenesis [27, 28].
Important properties of BM on day 15 are hypocellularity and a marked propor-
tion of debris, that is, destroyed cells under the effect of systemic chemotherapy 
[29, 30]. This requires modification of FC protocols for MRD monitoring, namely 
use of special dies able to identify viable, not destroyed cells in specimens. Our 
study showed reasonable to use Syto nucleotropic dies that can clearly select NC 
and as a consequence help to avoid debris dilution that may result in a considerable 
underestimation of MRD count and interfere with risk stratification.
By the end of induction chemotherapy, appearance (regeneration) of normal 
B-lineage progenitors in BM makes MRD detection more difficult. Clear-cut 
distinguishing between MRD cells and regenerating BCP is possible basing on LAIP 
or aberrant immunophenotype.
Aberrance is currently defined as follows:
1. Different levels of Ag expressions (overexpression of some molecules [CD58, 
CD10, CD9], low or no expression of Ag such as CD38, CD81)
2. Expression of Ag of uncommon differentiation lineages (e.g., co-expression of 
myeloid Ag such as CD13, CD33, CD66c, CD123 on tumor blasts)
3. Asynchronous expression of lineage-specific Ag (expression of Ag of mature 
B-cells, e.g., CD20 on CD34+ BCP)
A combination of CD58 and CD38 is the most frequently used Ag combination 
for assessment of B-lymphoblast immunophenotype aberrance in the AIEOP-BFM 
and COG FC protocols.
Normal BCP are characterized by CD58+/low/CD38+/++ immunophenotype, while 
aberrant immunophenotypes demonstrate CD58 overexpression and no or low 
CD38 expression.
As shown by the I-BFM-ALL-MRD Study group, CD58 overexpression is present 
on overwhelming majority of tumor B-lymphoblasts and is found in 93.5% of cases 
[31, 32, 19].
CD38 molecule with receptor and enzymatic activities that is involved in B- and 
T-cell ontogenesis is brightly expressed on normal BM progenitor cells. Low CD38 
expression in BCP is considered aberrant [19, 41] and is found in 61.2% of B-ALL 
according to Min Xia et al.
In our study, CD58 was overexpressed in 71.7% of B-ALL cases, that is, less fre-
quently that by literature data. An explanation may be that the boundary between 
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Ag normal and overexpression may be unclear. To make a more accurate evaluation 
of aberrant immunophenotype in primary diagnosis, Ag tumor expression should 
be compared with the number of residual normal BCP that is not always large. To 
make visualization more determinant, one has to select a considerable amount of 
cells (≥1 million), which was not possible in early studies.
There were only 58.6% of ALL with aberrant (low) CD38 expression which was 
in accord with foreign data.
If one of two Ag is not aberrant, MRD may be assessed basing on alternative 
combinations such as CD58/CD10, CD58/CD34, CD38/CD10, and CD38/CD34.
Of note, in our study, about one fourth of all cases (24.0%) had tumor 
B-lymphoblasts with no aberrance by this Ag combination. Therefore, additional 
criteria to identify aberrant immunophenotype are needed.
This requires MRD criteria to be used at time of diagnosis and most informa-
tive MRD markers to be selected in every specific case at the stage of ALL primary 
diagnosis.
Multicolor FC that simultaneously evaluates up to 12 various cell characteristics 
makes the most complete characterization of LAIP. This approach may be imple-
mented by use of the EuroFlow consortium 8-color panels with optimal combina-
tion of stable markers and fluorochromes [33–35].
The panel for more accurate B-ALL diagnosis includes 3 basic (repeated in all 
specimens) Ag and 20 specific Ag. This helps to make multiple aberrance evaluation 
by expression of nonlineage-specific CD45, CD58, CD38, CD9, CD123, and CD81; 
by expression of noncommon differentiation lineages such as pan-myeloid CD13, 
CD33, CD66c, CD15, CD65; and by asynchronous expression of Ag of different 
stages of B-cell differentiation CD10, CD34, CD, CD22, CD20, CD21, CD24. It is of 
much importance that expression of all above-mentioned markers may be assessed 
within a single cell population, that is, CD19+CD34+CD45low BCP.
The protocol makes possible indirect prediction of clinically significant abnor-
malities basing on a proper immunophenotype [36]. For instance, immunophe-
notypes of cells with mutations BCR-ABL, MLL, Tel-AML-1, and E2APBX1 are 
described.
When analyzing capacities of EuroFlow 8-color protocols with respect to MRD 
monitoring, we paid attention to CD81 [35]. The CD81 molecule belongs to the tet-
raspanin family and is directly associated with CD19, thus forming a signal complex 
CD19-CD21-CD81 that realizes its functional activity in normal B-cell ontogenesis. 
By the literature [37], aberrant (weak) CD81 expression is found in 82% of B-ALL 
cases. Our evaluation of CD81 expression in primary diagnosis coincided with 
international study data. For instance, aberrant expression was found in 85.7% of 
primarily diagnosed ALL.
Another molecule from the tetraspanin family is of interest as a criterion for MRD 
detection, that is, CD9 [38–40]. Its expression is evaluated both in 4- and 6-color FC 
protocols of the COG study group (M. Borowitz). CD9 is brightly expressed on early 
BCP, disappears at the pre-B stage, and appears again on mature B-cells. Its mono-
morphic overexpression on BCP is considered aberrant. In our study, 87.5% of B-ALL 
cases demonstrated CD9 aberrant expression on tumor B-lymphoblasts.
In case of monomorphous co-expression of myeloid Ag such as CD13, CD33 
and CD66c [31, 41] and also CD123 [42], they may be used as LAIP of tumor 
B-lymphoblasts. Prognostic significance of myeloid Ag co-expression on tumor 
cells is disputable, though CD66c (KORSA) is shown to be associated with BCR/
ABL1 reconstructions [43, 44]. N. Guillaume et al. analyzed immunophenotype 
of ALL from BCP to discover CD66c co-expression to be the most frequent 
(40.0%), while pan-myeloid Ag CD13 and CD33 were detected in 15.0% of cases 
only.
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In our evaluation of primary immunophenotype of tumor B-lymphoblasts, 
CD66c co-expression was found in 75.0% of cases, while CD13 and CD33 were pres-
ent in 46.0%, which is similar to international study data.
As concerns interleukin-3 receptor α-chain (CD123), all B-ALL were aberrant (i.e., 
the Ag was expressed on tumor cells), which is in accord with L. Munoz et al. [45].
Asynchronous expression of Ag of noncharacteristic differentiation lineages 
is an additional criterion for tumor B-lymphocyte LAIP. CD20 is such a marker in 
CD20-positive B-ALL whose expression is characteristic of mature B-cells only. 
However, CD20 co-expression on tumor B-lymphoblasts is found in 6.4–15.3% of 
B-ALL [29, 30]. CD20 is included in most FC panels for MRD diagnosis though 
it is appropriate rather for more clear-cut identification of CD20− BCP than for 
evaluation of its aberrant expression. This finding may be explained by a small 
cohort of B-ALL patients (up to 16.0% of all B-ALL patients) in whom residual 
blasts may be identified on the basis of CD34+CD20− immunophenotype. In our 
study, only 14.7% of ALL patients demonstrated CD20 co-expression on tumor 
B-lymphoblasts.
So in terms of FC approaches to evaluation of small populations which may also 
include MRD determination of LAIP is most effective using a combination of two 
Ag with aberrance manifesting itself as overexpression or a combination of mol-
ecules with over- and low/no expression. We propose the following Ag combina-
tions: CD123+CD81low, and CD9++CD81low.
Remission completeness is clinically assessed on day 33 of treatment. In our 
study, MRD-negative status was detected in 600% of patients.
Most patients (65.0%) receiving treatment by ALL IC BFM 2009 schedule were 
stratified into the intermediate risk group by MRD content.
Day 78 of treatment (end of consolidation induction) is the third time point 
with undoubted prognostic value for MRD detection. Basing on this evaluation, a 
group of so called slow response may be identified basing on MRD status. These 
patients are MRD-positive on days 15 and 33 and reach MRD negativity by day 78 
only. This cohort is characterized by good prognosis.
In our study, 64.3% of patients were MRD negative, with 7 of 14 patients 
followed-up in all the three points belonging to the slow response group.
Tumor immunophenotyping in disease recurrence is of special interest. Changes 
in Ag expression during treatment are studied and described rather well. According 
to international study data, changes as compared to disease onset may occur also in 
tumor cell immunophenotype in disease recurrence.
We assessed blast immunophenotype both in disease onset and relapse in five 
patients. Tumor blast immunophenotype was the same by the main diagnostic Ag in 
disease onset and recurrence in four of the five patients. Of interest is that change in 
blast phenotype as concerns intensity of CD58/CD38 expression versus the primary 
diagnosis was found in two of the five patients.
Clinical value of immunophenotype change as concern aberrance markers needs 
further clarification and may become an additional criterion in the protocol.
Novel targeted therapies that influence disease at molecular level are imple-
mented in clinical practice every year and many are at various stages of clinical trial.
A new stage of progress in targeted therapy is associated with development 
of biospecific antibodies that are a new class of monoclonal antibodies (MAb) 
binding with a surface antigen target, on the one hand, and with T-cell receptor, 
on the other hand, thus recruiting effector T-cells and enhancing tumor response. 
Blinatumomab (Blinzito) is the first therapy in this class that is approved by FDA 
for the treatment of Ph-negative refractory/relapse ALL from B-LP [38]. This 
approval was based on results of phase II clinical trials with 43% of 189 adults 
achieving complete response and 82% achieving MRD-negativity [46].
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Notwithstanding initial treatment results, some patients fail to respond to blinatu-
momab or develop progressive disease after initial response. Recurrence rate is 30%.
Characterization of blast immunophenotype in recurrence on blinatumomab 
therapy discovered no CD19 expression on tumor cells. This interferes with BCP 
identification and requires new methodological approaches to MRD assessment.
Inclusion of blinatumomab into B-ALL therapy requires an alternative MRD 
evaluation strategy.
There was one patient receiving blinatumomab in our study [47]. The MRD 
monitoring and immunophenotyping at second recurrence was difficult due to the 
absence of CD19+ B-cells. An algorithm for BCP detection was proposed and tested 
that was based on alternative B-lineage differentiation markers. Nuclear nuTdT in 
combination with cytoplasmatic CD22 as most stably expressed Ag were chosen.
So, given the appearance of new targeted therapies, FC algorithms for both MRD 
diagnosis and monitoring require certain flexibility and timely rational changes.
There is an equivocal situation with T-ALL. On the one hand, search for aberrant 
immunophenotype for TCP ended in failure. Expression of main Ag studied with 
respect to LAIP, that is, CD99 and nuTdT is variable [21]. On the other hand, taking 
into account normal T-cell ontogenesis, MRD assessment may be based on the 
absence of TCP of the cyCD3++smCD3−nuTdT+CD7+ level in BM. One has therefore 
just to assess TCP number in order to quantify MRD at any therapy stage.
Correct choice of antibody CD3 clone is of much importance for TCP identi-
fication. For instance, clone UCHT1 should be used to detect CD3 cytoplasmatic 
expression, while CD7 is needed to detect the membrane determinant.
The AIEOP-BFM protocol suggests that MRD detection in T-ALL should be 
based on CD7.
We compared the two approaches to TCP identification to find optimal TCP 
detection with CD7+/++smCD3+ immunophenotype within cyCD3+ population bas-
ing on T-cell ontogenesis.
All T-ALL patients in our study were stratified into the intermediate and high 
risk groups. According to MRD levels on day 15, most patients remained in the 
initial stratification group though 25.0% were transferred from the intermediate 
into the high risk group.
Of note that all patients demonstrated MRD-positivity on day 15, that is, none 
of the T-ALL patients achieved complete leukemic cytoreduction on ALL-IC-BFM 
2009 therapy.
So, clinical significance of MRD in ALL arises no doubt. It is reasonable to make 
MRD quantification immunologically using FC assay.
Since there are no normal BCP on day 15 of induction chemotherapy, MRD 
quantification in case of pre-pre-B and pre-B ALL immunosubtypes should be 
based on detection of CD10+/CD34+ population within CD19+ B-cells. In case of 
pro-B (CD10− and/or CD34−), ALL immunosubtype MRD detection should be 
based on expression of nuclear nuTdT in combination with cyCD22.
During BM regeneration (end of remission induction therapy and long-term 
treatment stages), MRD quantification is based on identification of BCP with aber-
rant immunosubtype. Alongside with the most common CD58/CD38, the following 
Ag should be used in LAIP assessment: CD81, CD9, CD13, CD33, CD66c, CD123, and 
CD20. At the stage of diagnosis, the most informative personalized Ag combinations 
should be selected for further MRD monitoring to make a more accurate risk stratifica-
tion of patients at different therapy stages and are an effective tool for its modification.
Tumor immunophenotype in disease recurrence should be compared with that 
in disease onset taking into account its possible changes.
In case of targeted therapy, for example, anti-recurrence treatment, FC protocol 
should be changed with respect to treatment features. For instance, BCP evaluation 
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Appendixes and nomenclature
Ab antibody
Ag antigene
ALOT acute leukemia orientation tube
ALL acute lymphoblastic leukemia
ALL-IC-BFM intercontinental acute lymphoblastic leukemia protocol of Berlin-
Frankfurt-Munster study group
B-ALL ALL from B-cell precursors
BCP B-cell precursors
BFM Berlin-Frankfurt-Munster study group
BM bone marrow
CD cluster of differentiation
cyCD cytoplasmic cluster of differentiation
COG children oncology group
FC flow cytometry
LAIP leukemia-associated immunophenotype
MAb monoclonal antibodies
MRD minimal residual disease
MNC mononuclear cells
NC nucleated cells
smCD membrane cluster of differentiation
T-ALL ALL from T-cell precursors
TCP T-cell precursors
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